<DOC>
	<DOC>NCT01816048</DOC>
	<brief_summary>The purpose of this study is to assess whether NaF PET/CT scans can be used to evaluate treatment response in bone metastases in subjects with prostate cancer treated with the investigational drug, TAK-700.</brief_summary>
	<brief_title>NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastasis</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Sodium Fluoride</mesh_term>
	<mesh_term>Fluorides</mesh_term>
	<mesh_term>Listerine</mesh_term>
	<criteria>Male patients 18 years or older Voluntary written consent Histologically proven adenocarcinoma of the prostate Evidence of radiographic bone metastases May have received prior chemotherapy for metastatic disease, but prior chemotherapy is not a requirement for eligibility Eastern Cooperative Oncology Group performance status 02 Serum testosterone level is less than or equal to 50 ng/dL Has undergone orchiectomy or plan to continue receiving gonadotropin releasing hormone (GnRH) analogue therapy Adequate organ function as measured by screening laboratory values specified in the protocol Must agree to use appropriate contraceptives prior to study procedures, during duration of study participation and for 4 months after last dose of TAK 700 Must be able to lie flat for greater than or equal to 30 minutes during PET/CT imaging Screening calculated ejection fraction of greater than or equal to 50% by multigated radionuclide angiography (MUGA) scan or Echocardiogram Received Strontium89, Samarium153, or other radioisotope within 3 months of registration history of allergic reactions attributed to compounds similar to sodium fluoride F18 (NaF) history of seizure disorder Known history of brain metastases Concurrent treatment with any herbal products within 7 days of study entry Received radiotherapy less than or equal to 4 weeks prior to registration Known hypersensitivity to TAK700 or related compounds Prior therapy for treatment of metastatic castrate resistant prostate cancer with any androgen biosynthesis inhibitor or androgen signaling pathway inhibitor such as: enzalutamide (MDV3100), abiraterone, ketoconazole, or aminoglutethimide Current bladder neck outlet obstruction Current spinal cord compression Current bilateral hydronephrosis History of adrenal insufficiency History of myocardial infarction, unstable symptomatic ischemic heart disease, ongoing arrhythmias (over grade 2), thromboembolic events, or any other cardiac condition within 6 months prior to first dose of study drug. Uncontrolled high blood pressure Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C Major surgery less than or equal to 4 weeks before the first dose of study drug Serious infection less than or equal to 2 weeks before the first dose of study drug Known gastrointestinal (GI) disease or GI procedure that could interfere with oral absorption or tolerance of TAK700, including difficulty swallowing capsules</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>prostate, prostate cancer</keyword>
</DOC>